

Regular Meeting of the

Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, September 16, 2021, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

Minutes (Open) - Approved

Members Present

Jimmy Lin, MD, Chair
Ali Alkoraishi, MD
Xuan Cung, PharmD
Laurie Nakahira, DO, Chief Medical Officer
Judy Ngo, PharmD
Peter Nguyen, DO
Jesse Parashar-Rokicki, MD

Members Absent

Dang Huynh, PharmD, Director of Pharmacy and UM
Dolly Goel, MD

Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist
Tami Otomo, PharmD, Clinical Pharmacist
Nancy Aguirre, Administrative Assistant

Others Present

Amy McCarty, PharmD, MedImpact

1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:04 pm. Roll call was taken and a quorum was established.

2. Public Comment

There were no public comments.

3. Open Meeting Minutes

The 2Q2021 P&T Committee open meeting minutes were reviewed.

It was moved, seconded and the open minutes of the 1Q2021 P&T meeting minutes were **unanimously approved**.

Motion: Dr. Nguyen

Second: Dr. Lin

Ayes: Dr. Alkoraishi, Dr. Cung, Dr. Nguyen, Dr. Parashar-Rokicki

Absent: Dr. Huynh, Dr. Goel, Dr. Ngo

4. Standing Agenda Items

a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, DO, Chief Medical Officer (CMO), presented the CMO Health Plan Updates. Dr. Nakahira reported the current Plan membership is approximately 286,552 members, reflecting a 9.1% increase over the last year, September 2020.

Dr. Nakahira announced the NCQA Cal MediConnect (CMC) Resurvey is coming up on January 31st-February 2nd, 2022. In addition, Cal AIM, Enhanced Care Management (ECM), and In Lieu of Services (ILOS) will begin on January 1st, 2022.

Currently, the Plan has placed a hold on returning to office, as the Delta variant continues to increase. The Committee Meetings will continue to be held via teleconference.

The Department of Health Care Services (DHCS) has initiated an incentive program to address the disparities of vaccines within the county. Approximately 56.9% of Medi-Cal (MC) members are fully vaccinated and 5.7% are partially vaccinated. Approximately 75.8% of CMC members are fully vaccinated and 4.5% are partially vaccinated.

Dr. Nakahira noted the Community Resource Center will be doing an opening kick-off on October 2nd, 2021. Vaccinations continue to be administered at the CRC.

Judy Ngo joined the meeting at 6:12p.m.

b. Medi-Cal Rx Update

Tami Otomo, PharmD, Clinical Pharmacist, noted the Medi-Cal (MC) Rx Carve Out will be implemented on January 1, 2022. Starting on this date, the pharmacy benefit for MC will be carved back into the state. DHCS will send a 60 day notice to members and the Plan will send a 30 day notice to members.

c. Plan/Global Medi-Cal Drug Use Review

i. Drug Utilization Evaluation Update

Tami Otomo, PharmD, Clinical Pharmacist, shared the results from SCFHP's quarterly retrospective Drug Use Evaluation (DUE) program. For Q3 2021, the focus was Asthma, specific to members receiving four or more prescriptions for an asthma medication over a 12-month period, who are not on a controller medication.

Adjourned to Closed Session at 6:21p.m.

Pursuant to Welfare and Institutions Code Section 14087.36 (w)

5. Closed Meeting Minutes

The 2Q2021 P&T Committee closed meeting minutes were reviewed.

It was moved, seconded and the closed minutes of the 2Q2021 P&T meeting minutes were unanimously approved.

Motion: Dr. Nguyen

Second: Dr. Alkoraishi

Ayes: Dr. Cung, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

Absent: Dr. Huynh, Dr. Goel

6. Metrics and Financial Updates

a. Membership Report

The Membership Report was presented by Dr. Nakahira during the CMO Update.

b. Pharmacy Dashboard

Dr. Otomo reviewed the Pharmacy Dashboard.

c. Pharmacy Member Portal Stats – 1H 2021

Dr. Otomo reviewed the Pharmacy Member Portal Stats – 1H 2021.

d. Drug Utilization & Spend – 1Q 2021

Amy McCarty, PharmD, MedImpact, presented the Drug Utilization and Spend for 1Q2021.

7. Discussion and Recommendations for Changes to SCFHP’s Cal MediConnect Formulary & Coverage Determination Criteria

a. Pharmacy Benefit Manager 2Q 2021 P&T Minutes

Dr. McCarty referenced the Pharmacy Benefit Manager 2Q 2021 P&T Minutes included in the meeting packet.

b. Pharmacy Benefit Manager 3Q 2021 P&T Part D Actions

Dr. McCarty reviewed the Pharmacy Benefit Manager 3Q 2021 P&T Part D Actions.

It was moved, seconded and the MedImpact Minutes and Actions were unanimously approved.

Motion: Dr. Nguyen

Second: Dr. Lin

Ayes: Dr. Alkoraishi, Dr. Cung, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki,

Absent: Dr. Huynh, Dr. Goel

8. Discussion and Recommendations for Changes to SCFHP’s Medi-Cal Formulary & Prior Authorization Criteria

a. Old Business/Follow-Up

Dr. Otomo reviewed a follow up of SGLT2i and SGLT2i combination products.

b. Formulary Modifications

Dr. Otomo reviewed the formulary changes.

It was moved, seconded and the Formulary Modification were unanimously approved.

Motion: Dr. Nguyen

Second: Dr. Alkoraishi

Ayes: Dr. Cung, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki,

Absent: Dr. Huynh, Dr. Goel

c. Fee-for-Service Contract Drug List Comparability

Dr. McCarty reviewed the Fee-for-Service (FFS) Contract Drug List (CDL) Comparability.

It was moved, seconded and the FFS Contract Drug List Comparability was unanimously approved.

Motion: Dr. Nguyen

Second: Dr. Alkoraishi

Ayes: Dr. Cung, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki,

Absent: Dr. Huynh, Dr. Goel

d. Prior Authorization Criteria

Dr. Nguyen reviewed the Prior Authorization Criteria.

ii. New or Revised Criteria

1. Vfend

iii. Annual Review

1. Compound Medications

2. Duragesic

3. Emend

4. Enablex

5. Enbrel
6. Insulin Pens
7. Myrbetrig
8. Nicotrol
9. Off-label
10. Opioid Safety Edits
11. Penlac
12. Quantity Limit
13. Retacrit
14. Taltz
15. Trintellix
16. Xelpros
17. Zyvox

It was moved, seconded and the Prior Authorization Criteria was **unanimously approved**.

Motion: Dr. Nguyen

Second: Dr. Cung

Ayes: Dr. Alkoraishi, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

Absent: Dr. Huynh, Dr. Goel

9. New Drugs and Class Reviews

a. Pneumococcal vaccines

Reviewed by Dr. McCarty.

b. Heart Failure Update – Jardiance & Entresto

Reviewed by Dr. McCarty.

c. Granulocyte Colony- Stimulating Factors (GCSF)

Reviewed by Dr. McCarty.

d. Xyrem & Xyway

Reviewed by Dr. McCarty.

e. Dupixent

Reviewed by Dr. McCarty.

f. New Entities & Combinations – Brexafemme, Accrufer, Azstarys

Reviewed by Dr. McCarty.

g. New Indications – Zeposia

Reviewed by Dr. McCarty.

h. COVID-19 Treatment - Sotrovimab

Reviewed by Dr. McCarty.

It was moved, seconded and the recommendations for New Drugs and Class Reviews were **unanimously approved**.

Motion: Dr. Nguyen

Second: Dr. Cung

Ayes: Dr. Alkoraishi, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

Absent: Dr. Huynh, Dr. Goel

Reconvene in Open Session at 7:51 p.m.

10. Discussion Items

a. New and Generic Pipeline

Dr. McCarty reviewed the New and Generic Pipeline. There were no notable generic drugs to review at this time.

11. Adjournment

The meeting adjourned at 7:54p.m. The next P&T Committee meeting will be on Thursday, December 16, 2021.

Jimmy Lin, MD, Chair

Date